key: cord-0692910-2qhmzyv2 authors: Meunier, Lucy; Sanavio, Mathilde; Dumortier, Jérôme; Meszaros, Magdalena; Faure, Stéphanie; Ursic Bedoya, José; Echenne, Maxime; Boillot, Olivier; Debourdeau, Antoine; Pageaux, Georges Philippe title: Mycophenolate mofetil decreases humoral responses to three doses of SARS‐CoV‐2 vaccine in liver transplant recipients date: 2022-04-02 journal: Liver Int DOI: 10.1111/liv.15258 sha: 9b7b89b1203b4ac75ef0d76c449d9c0a6ad771bb doc_id: 692910 cord_uid: 2qhmzyv2 BACKGROUND AND AIMS: After 2 doses, the efficacy of anti‐SARS‐CoV‐2 vaccination seems to be lower in solid organ transplant recipients than in the immunocompetent population. The objective of this study was to determine the humoral response rate after vaccination, including with a booster dose, and to identify risk factors for non‐responsiveness in liver transplant recipients. METHODS: We included all patients seen in consultation in two French liver transplant centres between January 1, 2021, and March 15, 2021. RESULTS: 598 liver transplant recipients were enrolled and 327 were included for analysis. Sixteen patients received one dose, 63 patients two doses and 248 patients three doses. Anti‐SARS‐Cov‐2 antibodies were detected in 242 out of 327 (74.0%) liver transplant patients after vaccination. Considering an optimal serologic response defined as an antibody titre >260 BAU/ml, 172 patients (52.6%) were responders. Mycophenolate mofetil (MMF) treatment was an independent risk factor for a failure to develop anti‐SARS‐CoV‐2 antibodies after vaccination (OR 0.458; 95%CI 0.258–0.813; p = .008). Conversely, male gender (OR 2.247, 95%CI 1.194–4.227; p = .012) and receiving an mRNA vaccine (vs a non‐mRNA vaccine) (OR 4.107, 95%CI 1.145–14.731; p = .030) were independent predictive factors for developing an optimal humoral response after vaccination. None of the patients who received the vaccine experienced any serious adverse events. CONCLUSIONS: Even after a third booster dose, response rate to vaccination is decreased in liver transplant recipients. MMF appears to be a major determinant of seroconversion and optimal response to vaccination in these patients. Anti-SARS-Cov-2 spike protein antibody detection was mostly performed using Elecsys Anti-SARS-CoV-2 S (Roche) and SARS-CoV-2 IgG II Quant test (Abbott Laboratories) and converted to universal unit (BAU/ml). 16 Patients were stratified into three groups based on antibody levels (BAU/mL): <0.4 (non-responders), 0.4-260 (partial responder), and >260 (responder). 17 For the univariate and multivariate analysis, patients were considered responders if antibodies >260 BAU/ml and non-responders if <260 BAU/ml. 17 Statistical analyses were performed using IBM SPSS Statistics version 28.0.0 (Inc., IL., USA). Continuous variables were presented as mean ± standard deviation. Categorical variables are presented as numbers and percentages. The relationship between categorical variables was assessed using the Chi-square test of Pearson or Fisher exact test if the theoretical numbers were below 5. The connection between a qualitative and a quantitative variable was evaluated using the Student's t test or the ANOVA test. The variables that had a p value <.20 in univariate analysis and those that had clinical relevance have been introduced in the multivariate analysis. The binary logistic regression model was used to identify independent predictive factors influencing the serologic response after the COVID vaccine. For all tests, statistical significance is set at p < .05. All procedures were conducted in accordance with the appropriate ethics and/or institutional review committee(s). The study was approved by the institutional review board (IRB, 202100907). Informed consent was obtained verbally and the IRB reviewed and approved the verbal consent process that was recorded in the electronic medical records. Between January 1, 2021, and March 15, 2021, 598 liver transplant recipients were enrolled in the study, 495 from centre 1 and 103 from centre 2. Of these, 103 received no anti-SARS-CoV-2, 13 had missing data (2 of which were diagnosed with Covid-19 disease during vaccination), and 155 were excluded from the analysis because they had serology within 28 days of vaccination ( Figure 1 ). Therefore, data The patient characteristics and their immunosuppressive regimens are shown in Table 1 . A majority of patients were men (214, 65.4%), with a mean age of 60 ± 13 years. The mean time from transplantation to the first vaccine dose was 7.60 ± 7.78 years. The most common indication for liver transplantation was alcohol-related liver disease (119, 36.4%), with the other indications listed in Table 1 . Anti-SARS-Cov-2 antibodies were detected in 242 out of 327 (74.0%) liver transplant patients after vaccination. With an optimal serologic response defined as an antibody titre >260 BAU/ml, 172 patients (52.6%) were responders and 70 (21%) had a partial serologic response (0.4 < antibody <260). In univariate analysis, history of COVID, MMF treatment and vaccine type predicted vaccine response ( Table 2 ). In a multivariate model including gender, age, dia- were independent predictive factors for developing an optimal humoral response after vaccination (Table 3 ). None of the patients who received the vaccine experienced any serious adverse events. Of the 598 patients who were offered a COVID-19 vaccination between January 1, 2021, and March 15, 2021, 103 did not receive the vaccine, 60 due to refusal and 43 because they were "waiting to decide". Several studies have reported a higher risk of severe COVID-19 disease and related mortality in SOT recipients and a lower vaccine response in these patients. 12 Despite seroconversion in 74% of our cohort, only 52.6% of patients had an optimal antibody level (> 260 BAU/ml) and a quarter of patients had no response, worse than expected for this population. Existing data on vaccine responses have not taken thresholds proposed to differentiate between partial and optimal responders into account. 18 For non-responders, protection strategies are limited to a fourth dose or an antibody cocktail (such as casirivimabimdevimab) for COVID-19 prophylaxis, 19 although the evolution of SARS-CoV-2 variants has led to a preference for tixagevimab/cilgavimab as prophylaxis in non-responders or partial responders. 20 Time between the last injection and COVID serology (days), mean (SD) 46 (28) 46 (26) .348 Number of immunosuppressive therapies, mean (SD) In conclusion, after three doses of vaccine, about half of the liver transplant recipients have an optimal response. MMF appears to be a major determinant of seroconversion and optimal response to vaccination in liver transplant recipients. The nature of immunosuppression must be considered to improve vaccine responses in liver transplant recipients and anti-SARS-CoV-2 mRNA vaccines are preferred in this population. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine Antibody response after a third dose of the mRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients with minimal serologic response to 2 doses Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients Effectiveness of SARS-CoV-2 vaccination in liver transplanted patients: the debate is open! SARS-CoV2-specific humoral and T-cell immune response after second vaccination in liver cirrhosis and transplant patients Unexpectedly high efficacy of SARS-CoV-2 BNT162b2 vaccine in liver versus kidney transplant recipients-is it related to immunosuppression only? Vaccines Effectiveness of SARS-CoV-2 vaccination in liver transplanted patients: The debate is open! Humoral immune response following SARS-CoV-2 vaccination in liver transplant recipients Coordinated cellular and humoral immune responses after two-dose SARS-CoV2 mRNA vaccination in liver transplant recipients Three doses of an mRNA Covid-19 vaccine in solid-organ transplant recipients Efficiency of a boost with a third dose of anti-SARS-CoV-2 messenger RNA-based vaccines in solid organ transplant recipients Vaccins contre la Covid-19: modalites d'administration des rappels Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study Covid-19 in liver transplant recipients: the French SOT COVID registry Predictive factors for humoral response after 2-dose SARS-CoV-2 vaccine in solid organ transplant patients Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19 Evusheld) for pre-exposure prophylaxis of COVID-19 Immunogenicity of SARS-CoV-2 BNT162b2 vaccine in solid organ transplant recipients Safety and immunogenicity of anti-SARS-CoV-2 messenger RNA vaccines in recipients of solid organ transplants Epidemiological pattern, incidence, and outcomes of COVID-19 in liver transplant patients High acceptance rate of COVID-19 vaccination in liver transplant recipients COVID-19 vaccine acceptance among liver transplant recipients Anti-SARS-CoV-2 spike protein and neutralizing antibodies at 1 and 3 months after three doses of SARS-CoV-2 vaccine in a large cohort of solid organ transplant patients Decreased long-term severe acute respiratory syndrome coronavirus 2-specific humoral immunity in liver transplantation recipients 12 months after coronavirus disease 2019 Mycophenolate mofetil decreases humoral responses to three doses of SARS-CoV-2 vaccine in liver transplant recipients